Intratumoral Treatment of Basal Cell Carcinoma (BCC) – Best-in-class cancer treatment
Oslo, Norway, May 19, 2022 /PRNewswire/ — CMD is a live event, open for physical participation at Hotel Continental Oslo, Norway, and a webcast. It starts at 14.00 CET and is expected to last approximately two hours, including a question and answer session.
The speakers will be:
Registration, physical or virtual attendance, before May 31, 2022at 14:00 CET:
Verrica Pharmaceuticals Inc. is a Nasdaq-listed dermatology treatment company headquartered in West Chester, Pennsylvania, to develop dermatological drugs that require medical intervention.exist August 2020, Lytix Biopharma announced a license agreement with Verrica to develop and commercialize LTX-315 for all malignant and precancerous dermatological indications (skin cancer). Verrica intends to initially focus on basal cell carcinoma and squamous cell carcinoma as lead indications for LTX-315 development. The American Cancer Society estimates that approximately 5.4 million cases of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are diagnosed in the United States each year. Since approximately 80% of these skin cancers are BCCs, new treatment options have enormous potential.
Ted WhiteCEO of Verrica Pharmaceuticals Inc. President and CEO of Verrica Pharmaceuticals since 2017 and a member of the Verrica Board of Directors since 2017 May 2018. Previously, he was President and General Manager of Almirall, a global pharmaceutical company and parent company of Aqua Pharmaceuticals, headquartered in Spain, specializing in medical dermatology. Before joining Aqua Pharmaceuticals, Mr. White held various positions at Novartis, including as a Managing Director.He has an MBA degree st joseph Bachelor’s Degree in College and General Arts Villanova University.
Gary GoldenbergChief Marketing Officer of Verrica Pharmaceuticals Inc. Chief Marketing Officer of Verrica since 2020. He served on the Verrica Board of Directors from 2018 to 2020.He is a medical and cosmetic dermatologist at Goldenberg Dermatology PC, where he April 2017Dr. Goldenberg also served as an Assistant Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai Hospital. New York City Assistant Professor of Dermatology at the school since 2009 University of Maryland School of Medicine From 2007 to 2009.he has Temple University Bachelor of Medicine and Biology LaSalle University. He completed his dermatology residency in Wake Forest University medical school and his fellowship in dermatopathology University of Colorado Health Sciences Center.
Prof. Aurélien Malabel, visiting professor Stanford University is a medical scientist with expertise in oncology (MD) and immunology (PhD). His clinical practice is dedicated to conducting early stage clinical trials of cancer immunotherapy in the Drug Development Unit (DITEP) at the Gustave Roussy Cancer Center. France. He leads a Translational Research Laboratory (LRTI) in the INSERM department of Prof. Lawrence Zitvogel Focus on the mechanism of action of immune-targeted therapy. He is also director of BIOTHERIS, a clinical research center dedicated to intratumoral immunotherapy (INSERM CIC1428). He is a full professor of clinical immunology at the University of Paris-Saclay.
Øystein Rekdal, CEO of Lytix Biopharma Co-founder of Lytix Biopharma with an extensive research background in tumor immunology, oncolytic peptides and their ability to induce potent tumor-specific immune responses. Dr. Rekdal’s postdoctoral research forms the basis of Lytix’s oncolytic molecular platform. Dr. Rekdal has begun collaborating with several distinguished researchers and institutions to further explore the unique ability of oncolytic molecules to reprogram non-inflammatory or inhibitory tumor microenvironments in experimental models and cancer patients.
Ole Peter NordbyHead of Investor Relations and Communications Manager
Email: [email protected]
mobile: +47 412 87 179
This information is provided to you by Cision http://news.cision.com
The following files are available for download:
SourceLytix Biopharma AS